Skip to main content

Table 1 Baseline characteristics of patients (n = 50)

From: Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Age (years)

Median

60

 
 

Range

34–76

 

Residual disease

Absent

17

(34%)

 

≤ 1 cm

6

(12%)

 

> 1 cm

23

(46%)

 

Surgery not performed

4

(8%)

Stage

IC

3

(6%)

 

II

6

(12%)

 

III

29

(58%)

 

IV

12

(24%)

PS

0

30

(60%)

 

1

18

(36%)

 

2

2

(4%)

Grading

1

2

(4%)

 

2

14

(28%)

 

3

22

(44%)

 

4

12

(24%)

Histologic type

Serous

30

(60%)

 

Mucinous

3

(6%)

 

Endometrioid

7

(14%

 

Undifferentiated

3

(6%)

 

Clear cell

1

(2%)

 

Mixed

4

(8%)

 

Other

2

(4%)

  1. PS = Performance Status